Patents by Inventor James Michael Crawforth

James Michael Crawforth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nicotinamide Derivatives
    Publication number: 20110306597
    Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions.
    Type: Application
    Filed: June 12, 2009
    Publication date: December 15, 2011
    Inventors: James Michael Crawforth, Paul Alan Glossop, Bruce Cameron Hamper, Wei Huang, Bradley Elwood Neal, Simon John Mantell, Kirk Olson, Atli Thorarensen, Steve Ronald Turner
  • Quinoline Derivatives as Neurokinin Receptor Antagonists
    Publication number: 20090143429
    Abstract: The present invention relates to substituted quinoline derivatives of Formula (I); wherein hal, n, A, formula (a), R1, R2, R3, R4, R5 and R6 are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.
    Type: Application
    Filed: July 25, 2006
    Publication date: June 4, 2009
    Inventors: James Michael Crawforth, Brian John Williams
  • Sulphones for inhibition of gamma secretase
    Patent number: 7161006
    Abstract: The invention provides compounds of formula I: which are inhibitors of ?-secretase and hence useful in the treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: January 9, 2007
    Assignee: Merck Sharp & Dohme Limited
    Inventors: James Michael Crawforth, Jason Matthew Elliott, Andrew Pate Owens, Francine Sternfeld
  • Imidazo-pyridine derivatives as ligands for GABA receptors
    Patent number: 6872731
    Abstract: A class of 3-phenylimidazo[1,2-a]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH-linkage, are selective ligands for GABAA receptors, in particular having high affinity for the ?2 and/or ?3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: March 29, 2005
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: James Michael Crawforth, Simon Charles Goodacre, Timothy Harrison, David James Hallett, Andrew Pate Owens, Michael Rowley, Martin Richard Teall
  • Imidazo-pyridine derivatives as ligands for gaba receptors
    Publication number: 20020188000
    Abstract: A class of 3-phenylimidazo[1,2-a]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Application
    Filed: May 23, 2002
    Publication date: December 12, 2002
    Inventors: James Michael Crawforth, Simon Charles Goodacre, Timothy Harrison, David James Hallett, Andrew Pate Owens, Michael Rowley, Martin Richard Teall
  • Tricyclic pyridin-2-one analogue as a GABA receptor ligand
    Publication number: 20010053776
    Abstract: 9-(4-Methylthiazol-2-yl)- 11-(pyridin-4-yl)-6,7-dihydro-5H-2, 7a-diazadibenzo[a,c]cyclohepten-8-one, and pharmaceutically acceptable salts thereof, are selective ligands for GABAA receptors, in particular having high affinity for the a2 and/or a3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Application
    Filed: May 18, 2001
    Publication date: December 20, 2001
    Inventors: James Michael Crawforth, Karl Richard Gibson, Michael Rowley